|
Postigo-Corrales F, Beltran-Videla A, Lazaro-Sanchez AD, Hurtado AM, Conesa-Zamora P, Arroyo AB, Luengo-Gil G. Docetaxel Resistance in Breast Cancer: Current Insights and Future Directions. Int J Mol Sci. 2025 Jul 23;26(15):7119. doi: 10.3390/ijms26157119. PubMed PMID: 40806254.
AÑO: 2025; IF: 4.9
|
40806254
|
Lago-Ballester F, Martinez-Orea A, Laorden-Carrasco A, Diaz-Carrasco MS, Titos-Arcos JC, Mira-Sirvent MC, Luengo-Gil G, Martinez-Penella M. Effectiveness and Safety of Sacituzumab Govitecan in Real-World Clinical Practice in Patients with Metastatic Triple-Negative and HR+/HER2-Negative Breast Cancer. Biomedicines. 2025 Aug 23;13(9):2059. doi: 10.3390/biomedicines13092059. PubMed PMID: 41007623; PubMed Central PMCID: PMC12467514.
AÑO: 2025; IF: 3.9
|
|
Lazaro Sanchez AD, Benitez Fuentes JD, Gil GL, Garcia MTG, Moreno EF, Zamora PC, Yago JB, Mohamed KM, Arroyo Rodriguez AB. Clinical and Proteomic Insights into a Cytokine Release Syndrome Triggered by Tebentafusp in a Metastatic Uveal Melanoma Patient: Case Report. J Clin Med. 2025 Feb 17;14(4):1333. doi: 10.3390/jcm14041333. PubMed PMID: 40004863; PubMed Central PMCID: PMC11856639.
AÑO: 2025; IF: 2.9
|
|
Perez-Parra D, Postigo-Corrales F, Cruz Santos AF, Sanchez-Espinosa A, Acosta-Ortega J, Carrillo-Vicente R, Lopez-Abellan MD, Conesa-Zamora P, Luengo-Gil G, Hurtado-Lopez AM. Characterization and Prognostic Impact of Fascin Expression in the Tumor Microenvironment of Triple-Negative Breast Cancer: Clues for a Tailored Therapy. Lab Invest. 2025 Nov 28:104268. doi: 10.1016/j.labinv.2025.104268. Online ahead of print. PubMed PMID: 41319754.
AÑO: 2025; IF: 4.2
|
|
Sanchez-Espinosa A, Garcia-Rodriguez J, Alonso-Aguirre V, Acosta-Ortega JM, Conesa-Zamora P, Garcia-Solano J, Luengo-Gil G. Expression of Fascin and DNA Topoisomerase 2-Alpha in Breast Carcinoma: Correlation with Histological Subtypes and Other Prognostic Markers. Int J Mol Sci. 2025 Mar 27;26(7):3076. doi: 10.3390/ijms26073076. PubMed PMID: 40243780; PubMed Central PMCID: PMC11988776.
AÑO: 2025; IF: 4.9
|